Protection against HPV
- Conditions
- Vaccination, HPV, Immunogenicity, Two-dose scheduleVaccinatie, HPV, immunogeniciteit, twee-doses schema
- Registration Number
- NL-OMON29611
- Lead Sponsor
- ational Institute for Public Health and The Environment, Bilthoven, the Netherlands
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 418
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all of the following
criteria:
Exclusion Criteria
A potential subject who meets any of the following criteria will be excluded from participation
in this study:
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cohort 1997-2000<br /><br>- Antibody responses of vaccine-induced types after a two dose schedule up to 4 1/2 years after the first dose.<br><br /><br /><br>Cohort 2001<br /><br>- Level and kinetics of vaccine-induced antibody response after a two dose schedule at approximately 7,12 and 24 months.<br>
- Secondary Outcome Measures
Name Time Method Cohort 1997-2000<br /><br>- Cross-protection<br><br /><br /><br>Cohort 2001<br /><br>- Avidity of antibodies <br /><br>- Cross-protection<br /><br>- Cellular immunity